Antibiotics
(Die Seite wurde neu angelegt: „ '''Anti microbials''' {{tp|p=32439730|t=2020. Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?|pdf=|usr=00…“) |
K |
||
| (7 dazwischenliegende Versionen von 2 Benutzern werden nicht angezeigt) | |||
| Zeile 1: | Zeile 1: | ||
| + | {{up|PHA retargeted compounds}} | ||
| + | {{qt|Azithromycin}} | ||
| + | |||
| + | {{tp|p=32744716|t=2020. SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential.|pdf=|usr=017}} | ||
'''Anti microbials''' | '''Anti microbials''' | ||
| Zeile 5: | Zeile 9: | ||
'''Macrolide antibiotics''' | '''Macrolide antibiotics''' | ||
{{tp|p=32249257|t=2020. Macrolide treatment for COVID-19: Will this be the way forward?|pdf=|usr=}} | {{tp|p=32249257|t=2020. Macrolide treatment for COVID-19: Will this be the way forward?|pdf=|usr=}} | ||
| + | {{tp|p=32546446|t=2020. Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?|pdf=|usr=011}} | ||
| + | |||
| + | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
'''Teicoplanin''' | '''Teicoplanin''' | ||
{{tp|p=32179150|t=ä. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?|pdf=|usr=}} | {{tp|p=32179150|t=ä. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?|pdf=|usr=}} | ||
{{tp|p=32454071|t=2020. Is teicoplanin a complementary treatment option for COVID-19? The question remains.|pdf=|usr=008}} | {{tp|p=32454071|t=2020. Is teicoplanin a complementary treatment option for COVID-19? The question remains.|pdf=|usr=008}} | ||
| − | + | {{tp|p=32593831|t=2020. Plausible role of combination of Chlorpromazine hydrochloride and Teicoplanin against COVID-19.|pdf=|usr=011}} | |
'''Doxycycline and other Tetracyclins''' | '''Doxycycline and other Tetracyclins''' | ||
| Zeile 24: | Zeile 25: | ||
{{tp|p=32533795|t=2020. Further aspects of doxycycline therapy in COVID-19.|pdf=|usr=008}} | {{tp|p=32533795|t=2020. Further aspects of doxycycline therapy in COVID-19.|pdf=|usr=008}} | ||
{{tp|p=32379302|t=2020. Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management.|pdf=|usr=008}} | {{tp|p=32379302|t=2020. Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management.|pdf=|usr=008}} | ||
| + | {{tp|p=32552044|t=2020. Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges.|pdf=|usr=010}} | ||
| + | {{tp|p=32574320|t=2020. Doxycycline: From Ocular Rosacea to COVID-19 Anosmia. New Insight Into the Coronavirus Outbreak.|pdf=|usr=011}} | ||
| + | {{tp|p=32566483|t=2020. Doxycycline as a potential partner of COVID-19 therapies.|pdf=|usr=011}} | ||
| + | |||
| + | '''Cefuroxime''' | ||
| + | {{tp|p=32538276|t=2020. Repurposing cefuroxime for treatment of COVID-19: a scoping review of in silico studies.|pdf=|usr=011}} | ||
| + | |||
| + | '''Aminoglycosides'' | ||
| + | {{tp|p=32554149|t=2020. Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy.|pdf=|usr=011}} | ||
'''Metronidazole''' retarget | '''Metronidazole''' retarget | ||
{{tp|p=32259129|t=2020. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen |pdf=|usr=}} | {{tp|p=32259129|t=2020. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen |pdf=|usr=}} | ||
| + | |||
| + | '''Paromomycin''' | ||
| + | {{tp|p=32579907|t=2020. Paromomycin: a potential dual targeted drug effectively inhibits both Spike (S1) and Main Protease of COVID-19.|pdf=|usr=010}} | ||
Aktuelle Version vom 11. April 2021, 20:20 Uhr
| PHA retargeted compounds |
| Azithromycin |
32744716 2020. SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential.
Anti microbials
32439730 2020. Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?
Macrolide antibiotics
32249257 2020. Macrolide treatment for COVID-19: Will this be the way forward?
32546446 2020. Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?
Teicoplanin
32179150 ä. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?
32454071 2020. Is teicoplanin a complementary treatment option for COVID-19? The question remains.
32593831 2020. Plausible role of combination of Chlorpromazine hydrochloride and Teicoplanin against COVID-19.
Doxycycline and other Tetracyclins
32339778 ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19
32314492 ä. Doxycycline, a widely used antibiotic in dermatology with a possible anti?inflammatory action against IL?6 in COVID?19 outbreak
32267566 2020. Therapeutic Potential for Tetracyclines in the Treatment of COVID-19
32533795 2020. Further aspects of doxycycline therapy in COVID-19.
32379302 2020. Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management.
32552044 2020. Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges.
32574320 2020. Doxycycline: From Ocular Rosacea to COVID-19 Anosmia. New Insight Into the Coronavirus Outbreak.
32566483 2020. Doxycycline as a potential partner of COVID-19 therapies.
Cefuroxime
32538276 2020. Repurposing cefuroxime for treatment of COVID-19: a scoping review of in silico studies.
'Aminoglycosides
32554149 2020. Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy.
Metronidazole retarget
32259129 2020. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen
Paromomycin
32579907 2020. Paromomycin: a potential dual targeted drug effectively inhibits both Spike (S1) and Main Protease of COVID-19.
